Literature DB >> 30730273

Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update.

Omar Abdel-Rahman1, Don Morris1.   

Abstract

Entities:  

Keywords:  NSCLC; immunotherapy; outcome; prognosis; survival

Mesh：

Substances：

Year:  2019        PMID： 30730273     DOI： 10.2217/imt-2018-0167

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  5 in total

1.  Immune Subtype Profiling and Establishment of Prognostic Immune-Related lncRNA Pairs in Human Ovarian Cancer.

Authors:  Xingling Wang; Jing Wang; Mingxin Yu
Journal:  Comput Math Methods Med       Date:  2022-05-05       Impact factor: 2.809

2.  Local control of locally advanced (N2) non-small cell lung cancer: when and how?

Authors:  Byung Jo Park; Jhingook Kim
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

Review 3.  Resistance to chemoimmunotherapy in non-small-cell lung cancer.

Authors:  Maximilian Johannes Hochmair
Journal:  Cancer Drug Resist       Date:  2020-07-12

4.  Bullatacin triggers immunogenic cell death of colon cancer cells by activating endoplasmic reticulum chaperones.

Authors:  Fangtian Fan; Peiliang Shen; Yue Ma; Wangbo Ma; Hongyan Wu; Hao Liu; Qing An
Journal:  J Inflamm (Lond)       Date:  2021-06-10       Impact factor: 4.981

Review 5.  Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response.

Authors:  Qingyang Xiao; André Nobre; Pilar Piñeiro; Miguel-Ángel Berciano-Guerrero; Emilio Alba; Manuel Cobo; Volker M Lauschke; Isabel Barragán
Journal:  J Clin Med       Date:  2020-01-20       Impact factor: 4.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.